Offering improved image clarity capable of capturing details of subtle pathology, the Magnetom Terra.X 7T MRI system reportedly features the first eight-channel parallel transmit architecture for clinical use.
The Magnetom Terra.X., a new 7T magnetic resonance imaging (MRI) system, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
A second-generation successor to the Magnetom Terra, the Magnetom Terra.X system has a number of attributes to provide enhanced 7T imaging, according to Siemens Healthineers, the manufacturer of Magnetom Terra.X.
The Magnetom Terra.X system, recently cleared by the FDA, has a number of features including the first eight-channel parallel transmit architecture for clinical use, according to Siemens Healthineers, the manufacturer of the 7T MRI system. (Image courtesy of Siemens Healthineers.)
The company said key features of the device include:
• the first eight-channel parallel transmit architecture for clinical use;
• deep learning image reconstruction specifically geared to 7T;
• improved diffusion imaging via a high-performance gradient system; and
• accelerated image acquisition capabilities that can facilitate high-resolution brain and knee exams in less than 20 minutes.
“The MAGNETOM Terra.X builds on our engineering achievements as pioneers in 7T MRI by providing the ultra-high-field community with the necessary tools to offer higher-quality patient care not just in neurological imaging, but also in the knee,” said Katie Grant, vice president of magnetic resonance at Siemens Healthineers North America.
Siemens Healthineers added that the FDA clearance includes upgrades of installed Magnetom Terra systems to the Magnetom Terra.X.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.